R A Furie Selected Research

abetimus

2/2001	Treatment of systemic lupus erythematosus with LJP 394.
1/2001	Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R A Furie Research Topics

Disease

4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2017 - 02/2001
2	Fatigue 01/2017 - 02/2016
2	Rheumatoid Arthritis 10/2000 - 01/2000
1	Chronic Disease (Chronic Diseases) 01/2017
1	Infections 09/2015
1	Neoplasms (Cancer) 09/2015
1	Proteinuria 09/2015
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 08/2001
1	Lupus Nephritis 01/2001

Drug/Important Bio-Agent (IBA)

3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2000
3	B-Cell Activating FactorIBA 01/2017 - 09/2015
2	Estrogens (Estrogen)FDA Link 01/2017 - 02/2016
2	AMG623 peptibodyIBA 01/2017 - 09/2015
2	Immunoglobulins (Immunoglobulin)IBA 02/2016 - 01/2000
2	AntibodiesIBA 02/2016 - 01/2001
2	abetimusIBA 02/2001 - 01/2001
1	Antinuclear AntibodiesIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	SRI-5 (SRI 5)IBA 02/2016
1	tabalumabIBA 02/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2016
1	Monoclonal AntibodiesIBA 02/2016
1	Complement System Proteins (Complement)IBA 02/2016
1	CreatineIBA 09/2015
1	Proteins (Proteins, Gene)FDA Link 09/2015
1	beta 2-Glycoprotein I (Apolipoprotein H)IBA 08/2001
1	AutoantibodiesIBA 08/2001
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 10/2000
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2000

Therapy/Procedure

2	Therapeutics 01/2017 - 02/2001